Dashboard
Manage Tickers

ALMS ALUMIS INC.

Nasdaq www.alumis.com


$ 7.08 $ -0.24 (-3.31 %)    

Thursday, 20-Nov-2025 14:18:35 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 589.02 $ -22.65 (-3.7 %)
DIA $ 459.24 $ -7.44 (-1.59 %)
SPY $ 655.47 $ -17.43 (-2.59 %)
TLT $ 89.24 $ 0.25 (0.28 %)
GLD $ 374.43 $ -0.75 (-0.2 %)
$ 6.57
$ 7.36
$ 7.02 x 194
$ 7.07 x 1,000
$ 7.00 - $ 7.45
$ 2.76 - $ 10.49
1,624,763
na
685.86M
$ -2.55
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-13-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 03-19-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

amer-sports-posts-upbeat-q3-earnings-joins-diginex-james-hardie-industries--and-other-big-stocks-moving-higher-on-tuesday
Amer Sports Posts Upbeat Q3 Earnings, Join...
11/18/2025 15:10:39

Core News & Articles
Alumis Q3 EPS $(1.06) Misses $(0.96) Estim...
11/13/2025 21:42:38

Alumis (NASDAQ:ALMS) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.96) by 1...

olema-pharmaceuticals-exelixis-genmab-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
Olema Pharmaceuticals, Exelixis, Genmab An...
10/20/2025 12:10:45

Core News & Articles
Reported Earlier, Apollomics Reverses Wind...
10/14/2025 04:58:08

Core News & Articles
HC Wainwright & Co. Reiterates Buy on Alum...
08/14/2025 11:55:34

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Alumis (NASDAQ:ALMS) with a Buy and maintains $14 price target.

Core News & Articles
Alumis Q2 Sales $2.67M Beat $2.00M Estimate
08/13/2025 20:28:24

Alumis (NASDAQ:ALMS) reported quarterly sales of $2.67 million which beat the analyst consensus estimate of $2.00 million by 33...

Core News & Articles
Wells Fargo Initiates Coverage On Alumis w...
07/25/2025 13:55:34

Wells Fargo analyst Derek Archila initiates coverage on Alumis (NASDAQ:ALMS) with a Overweight rating and announces Price Ta...

Core News & Articles
HC Wainwright & Co. Reiterates Buy on Alum...
07/25/2025 11:05:09

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Alumis (NASDAQ:ALMS) with a Buy and maintains $14 price target.

Core News & Articles
Alumis Completes Patient Enrollment In Glo...
07/24/2025 11:35:01

Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immun...

Core News & Articles
Alumis Files For Mixed Shelf Offering Of U...
07/03/2025 18:59:20

- SEC Filing

Core News & Articles
Guggenheim Reinstates Buy on Alumis, Annou...
06/10/2025 14:52:22

Guggenheim analyst Yatin Suneja reinstates Alumis (NASDAQ:ALMS) with a Buy and announces $18 price target.

Core News & Articles
Alumis Completes Patient Enrollment In Piv...
05/29/2025 11:56:51

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
05/20/2025 17:05:51

Core News & Articles
Oppenheimer Maintains Outperform on Alumis...
05/15/2025 18:09:48

Oppenheimer analyst Jeff Jones maintains Alumis (NASDAQ:ALMS) with a Outperform and lowers the price target from $26 to $25.

Core News & Articles
Alumis Q1 Sales $17.39M
05/14/2025 20:29:21

Alumis (NASDAQ:ALMS) reported $17.39 million in sales this quarter.

Core News & Articles
ACELYRIN Stockholders Approve Merger With ...
05/13/2025 17:07:40

ACELYRIN, Inc. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of t...

Core News & Articles
Lumis Stockholders Approve All Proposals R...
05/13/2025 17:03:00

lumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimiz...

Core News & Articles
HC Wainwright & Co. Reiterates Buy on Alum...
04/30/2025 10:36:22

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Alumis (NASDAQ:ALMS) with a Buy and maintains $14 price target.

charles-schwab-to-rally-around-24-here-are-10-top-analyst-forecasts-for-tuesday
Charles Schwab To Rally Around 24%? Here A...
04/22/2025 13:37:04

Core News & Articles
HC Wainwright & Co. Maintains Buy on Alumi...
04/22/2025 10:36:10

HC Wainwright & Co. analyst Mitchell Kapoor maintains Alumis (NASDAQ:ALMS) with a Buy and lowers the price target from $...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION